RUBY
Price:
$0.083
Market Cap:
$0
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.[Read more]
Industry
Biotechnology
IPO Date
2018-07-18
Stock Exchange
NASDAQ
Ticker
RUBY
According to Rubius Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is -13765000.00. This represents a change of -108.03% compared to the average of 171.36M of the last 4 quarters.
The mean historical Enterprise Value of Rubius Therapeutics, Inc. over the last ten years is 405.51M. The current -13765000.00 Enterprise Value has changed -439.45% with respect to the historical average. Over the past ten years (40 quarters), RUBY's Enterprise Value was at its highest in in the June 2021 quarter at 2.02B. The Enterprise Value was at its lowest in in the March 2017 quarter at 0.
Average
405.51M
Median
394.94M
Minimum
2.04M
Maximum
752.65M
Discovering the peaks and valleys of Rubius Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 264.65%
Maximum Annual Enterprise Value = 752.65M
Minimum Annual Increase = -99.72%
Minimum Annual Enterprise Value = 2.04M
Year | Enterprise Value | Change |
---|---|---|
2022 | 2.04M | -99.72% |
2021 | 738.97M | 15.93% |
2020 | 637.43M | -15.31% |
2019 | 752.65M | 90.57% |
2018 | 394.94M | 264.65% |
2017 | 108.31M | -46.97% |
The current Enterprise Value of Rubius Therapeutics, Inc. (RUBY) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
459.48M
5-year avg
505.20M
10-year avg
405.51M
Rubius Therapeutics, Inc.’s Enterprise Value is greater than Magenta Therapeutics, Inc. (-114170976.00), less than Evelo Biosciences, Inc. (16.71M), greater than AVROBIO, Inc. (-85302404.00), less than Scholar Rock Holding Corporation (2.79B), less than Replimune Group, Inc. (984.10M),
Company | Enterprise Value | Market cap |
---|---|---|
-114170976.00 | $42.44M | |
16.71M | $28.47K | |
-85302404.00 | $5.24M | |
2.79B | $2.80B | |
984.10M | $1.02B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Rubius Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Rubius Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Rubius Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Rubius Therapeutics, Inc. (RUBY)?
What is the 3-year average Enterprise Value for Rubius Therapeutics, Inc. (RUBY)?
What is the 5-year average Enterprise Value for Rubius Therapeutics, Inc. (RUBY)?
How does the current Enterprise Value for Rubius Therapeutics, Inc. (RUBY) compare to its historical average?